Team
Companies
About
Latest
Contact
LP Portal
Resources
WoVen
Canaan on Twitter
Canaan on LinkedIn
© Copyright 2019 Canaan |
Legal
Team
Companies
About
Latest
Articles Tagged 'Biopharma'
Xconomy: With $9.5M, Intrepida Bio launches to target pancreatic cancer & more
FierceBiotech: Nocion Therapeutics named to Fierce 15
WoVen Podcast: Working with grit (and a patient's perspective) in women’s health -- A conversation with Gail Maderis
FierceBiotech: A personalized CAR-T to attack every solid tumor? PACT Pharma has a plan
MedCityNews: Pact Pharma enrolls first patients in Phase Ia/Ib solid tumor cell therapy study
Wired: These protein picker-uppers keep your cells clean and healthy
Endpoints News: Bayer enlists Arvinas on two-pronged protein degradation effort, foraying into agtech
Welcome Nils Lonberg
Tim Shannon in BioCentury: Making orphan drug prices work for society
Endpoints News: Four biotechs, including NextCure, haul in $303M+ from a fresh burst of IPOs
Business Insider: Scientists are working on cancer treatments that attack the disease's 'Holy Grail"
STAT News: Nils Lonberg, the entrepreneur behind the cancer immunotherapy revolution
STAT News: Arrakis' lofty goal: Kill cancer with pills that target RNA instead of proteins
FierceBiotech: Nocion launches with $27M and 'charged drugs' to selectively target pain
Business Insider: Nocion raises $27M to make a new kind of painkiller as the race to replace opioids heats up
STAT News: How one company, Nocion, thinks unraveling cough can provide a new way to treat pain
Julie Grant: Announcing Nocion Therapeutics, a novel approach to neurogenic inflammation
Nature: Protein-slaying drugs could be the next blockbuster therapies
Nature Reviews: First targeted protein degrader, developed by Arvinas, hits the clinic
BioCentury: Wende Hutton on mapping microbiome manufacturing
Endpoints News: Canaan leaps into UK biotech, co-leading $14M Series A for upstart Grey Wolf
Business Insider: Wende Hutton and top VCs give their best 2019 predictions for healthcare
SF Business Times: Antiva CEO draws on personal experience to fuel drug development
Nasdaq: Cancer biotech Arvinas prices upsized IPO at $16
Business Insider: Julie Grant named 40-and-under Silicon Valley biotech investing star
STAT News: Antiva tried to drum up interest for a much-needed drug. Many men didn’t get it
Nina Kjellson: "Jumping together" to move the field of personalized cancer therapy
BioCentury: Why GV and Canaan backed PACT Pharma's hyperpersonalized cancer approach
Endpoints News: Brent Aherns weights in on FDA's new reimbursement idea for antibiotics
Tim Shannon: More hope for cystic fibrosis treatment, and still more to do
Endpoints: Virtual biotech Antiva sets out on a big R&D quest, armed with a $22 million round for an HPV therapy
Scientific American: New thalidomide-like therapy hijacks cells’ trash-disposal system
Fierce Biotech: Mackay’s Rallybio rare disease startup raises $37M in first funding round
Nina Kjellson: Practical tips from two male biotech CEOs who are leaning in
IDEAYA & the Next Frontier in Synthetic Lethality
Business Insider: Wende Hutton shares her best career advice